Medtronic (NYSE:MDT) announced its intention to separate its diabetes business into a new, standalone company, to enhance focus on high-margin growth drivers for Medtronic and accelerate innovation ...

After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of ...

Medtronic (NYSE: MDT) announced some personnel moves, including the departure of a longtime leader across multiple business ...

With both MDT & ABT focusing on their core strengths, the stage is set for a compelling comparison. Let's see which stock is ...

Medtronic, a healthcare technology company based in Ireland, plans to separate its diabetes business into a standalone, publicly traded company by the end of 2026.  The company announced the move May ...

His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech ...

While some analysts questioned why Medtronic would leave a fast-growing market, others backed the company’s plan to focus on ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced its intent to separate its Diabetes ...

Medtronic (NYSE:MDT) reported better-than-expected fiscal Q4 earnings and revenue, while unveiling plans to spin off its ...

Global medical device company Medtronic announced Wednesday that it intends to separate its diabetes business into a ...

The medical device giant, which is domiciled in Dublin, Ireland but has its main office in Fridley, Minnesota, confirmed that ...

Medtronic has unveiled plans to spin off its diabetes unit into its own publicly traded company that would be headquartered ...